"There are now 26 pharma manufacturers with most-favored-nation deals—that represents about 89% of the branded drug market."

John Solomon notes that President Donald J. Trump expanded the most-favored-nation drug pricing initiative by securing agreements with nine additional pharmaceutical companies, slashing costs across nearly 90% of the branded drug market for critical conditions like cancer, Parkinson's, and liver disease.